Business Context and Reporting Period
Company: Clearmind Medicine Inc.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: November 13, 2025
Context: The Company announced a definitive securities purchase agreement for a registered direct offering (the "Offering") to raise capital for general corporate purposes, including research and development and clinical testing.
Key Financial Metrics and Transaction Details
- Offering Structure: Sale of 958,222 Common Shares and Pre-Funded Warrants to purchase up to 2,984,146 Common Shares.
- Purchase Price: $0.20 per Common Share; $0.1999 per Pre-Funded Warrant.
- Expected Gross Proceeds: Approximately $0.788 million.
- Use of Proceeds: Operating expenses, R&D (clinical/pre-clinical testing), working capital, future acquisitions, and capital expenditures.
- Warrant Terms: Immediately exercisable at $0.0001 per share; cashless exercise permitted; subject to a 4.99% beneficial ownership limitation.
Note: This filing does not provide historical revenue, profit, cash flow, margin, debt, or liquidity metrics.
Material Changes
This filing reports a material capital event rather than a change in operating performance. The Company is increasing its share count through the issuance of new Common Shares and Pre-Funded Warrants. The filing does not provide comparative financial data against prior periods.
Outlook, Risks, and Contingencies
- Closing Date: Expected on or about November 14, 2025, subject to customary closing conditions.
- Contingencies: The Offering may not close if conditions are not satisfied or specified contingencies do not occur.
- Forward-Looking Statements: The Company cautions that forward-looking statements regarding the closing and use of proceeds are not guaranteed and are subject to risks beyond its control.
- Regulatory Status: Securities are issued pursuant to a prospectus supplement filed under an effective shelf registration statement (Form F-3).
Investor Verification Checklist
- Verify the final closing of the Offering and the actual amount of net proceeds received.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and conditions.
- Monitor the Company's cash position to assess runway for clinical trials post-offering.
- Check for any subsequent filings regarding the exercise of Pre-Funded Warrants and resulting dilution.